USANA Health Sciences Inc (USNA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at USANA Health Sciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 22.10 $ — 34% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 76.5% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 1
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.12 | 2.12 – 2.12 | 945 | 9.8% | 1 |
| 12/31/2027 | 2.77 | 2.77 – 2.77 | 1,002 | 30.7% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.43 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.23 | -73.00 | 214 | -3.40 | 2.10 | 6 | 4 |
| 2025: Q1 | 0.49 | -42.50 | 250 | 9.50 | 3.80 | 16 | 13 |
| 2025: Q2 | 0.52 | -4.30 | 236 | 10.80 | 4.10 | 12 | 7 |
| 2025: Q3 | -0.36 | -164.10 | 214 | 6.70 | -3.10 | -2 | -5 |
| 2025: Q4 | -0.10 | -141.30 | 226 | 5.90 | -0.80 | -3 | -6 |
| 2026: Q1 | 0.41 | -17.10 | 250 | 0.30 | 3.00 | 10 | 7 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,006 | 139 | 100 | 3.99 | 137 | 325 | 471 |
| 2017 | 1,047 | 133 | 63 | 2.53 | 124 | 363 | 519 |
| 2018 | 1,189 | 188 | 126 | 5.12 | 152 | 391 | 554 |
| 2019 | 1,061 | 146 | 101 | 4.41 | 127 | 352 | 517 |
| 2020 | 1,135 | 176 | 125 | 5.86 | 160 | 442 | 641 |
| 2021 | 1,186 | 170 | 117 | 5.73 | 121 | 395 | 578 |
| 2022 | 999 | 108 | 69 | 3.59 | 104 | 434 | 597 |
| 2023 | 921 | 93 | 64 | 3.30 | 71 | 497 | 633 |
| 2024 | 855 | 66 | 42 | 2.19 | 61 | 532 | 748 |
| 2025 | 925 | 51 | 11 | 0.58 | 22 | 533 | 743 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe.
| Employees | 1,570 |
|---|---|
| Headquarters | Salt Lake City, UT |
| Address | 3838 West Parkway Boulevard, 84120 Salt Lake City, United States |
| Phone | 801 954 7100 |
| Website | usana.com |
| IPO Date | 25. Jul 1996 |
| ISIN | US90328M1071 |
| Stock Split | 2:1 on 11/23/2016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Kevin G. Guest | CEO & Executive Chairman | 1963 |
| G. Douglas Hekking | Chief Financial Officer | 1970 |
| Walter Noot | Chief Operating Officer | 1966 |
| P. Joshua Foukas J.D. | Chief Legal Officer, General Counsel & Corporate Secretary | 1976 |
| Brent L. Neidig | Chief Commercial Officer | 1984 |
| Myron W. Wentz Ph.D. | Founder & Chairman Emeritus | 1941 |
| John Cuomo | Executive Director of Product Development & Technology | – |
| Peter Benedict | Chief Information Officer | – |
| Kathryn Armstrong Ph.D. | Chief Scientific Officer | 1981 |
| Patrique Richards | Executive Director of Investor Relations & Business Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 25. Jul 2026 | Armstrong Kathryn Michelle | CHIEF SCIENTIFIC OFFICER | Other | 518 | 21.32 | 11,044 |
| 25. Jul 2026 | Armstrong Kathryn Michelle | CHIEF SCIENTIFIC OFFICER | Other | 1,166 | – | – |
| 25. Jul 2026 | Benedict Peter | CHIEF INFORMATION OFFICER | Other | 176 | 21.32 | 3,752 |
| 25. Jul 2026 | Benedict Peter | CHIEF INFORMATION OFFICER | Other | 598 | – | – |
| 23. Jul 2026 | Ding Xia | Director | Other | 604 | 20.92 | 12,636 |
| 23. Jul 2026 | Ding Xia | Director | Other | 1,632 | – | – |
| 23. Jul 2026 | Fleming John Turman | Director | Other | 1,632 | – | – |
| 23. Jul 2026 | Pelosi Peggie | Director | Other | 935 | 20.92 | 19,560 |
| 23. Jul 2026 | Pelosi Peggie | Director | Other | 1,632 | – | – |
| 23. Jul 2026 | Nixon J Scott | Director | Other | 1,632 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.